COVID-19 Updates: COVID-19 Resources » Vaccine Update » Updated Visitor Policy » What We're Doing to Keep You Safe »
Trial ID or NCT#
NCT00822900
Status
NOT RECRUITING
Purpose
The ProTECT study will determine if intravenous (IV) progesterone (started within 4 hours of injury and given for a total of 96 hours), is more effective than placebo for treating victims of moderate to severe acute traumatic brain injury.
Official Title
Phase 3 Clinical Trial to Determine if Progesterone Along With Standard Medical Care for Brain Injury is More Effective at Limiting the Amount of Damage Cause by a Traumatic Brain Injury Than Standard Medical Care Alone.
Eligibility Criteria
Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Investigator(s)
James Quinn
Emergency medicine doctor,
Pediatric emergency medicine doctor
Professor of Emergency Medicine at the Stanford University Medical Center
Chitra Venkatasubramanian, MBBS, MD
Neurocritical care specialist,
Stroke and vascular neurologist
Clinical Professor, Neurology & Neurological Sciences
Anna Finley Caulfield, MD
Neurocritical care specialist
Clinical Associate Professor, Neurology & Neurological Sciences
Contact us to find out if this trial is right for you.
CONTACT
Rosen Mann
(650) 721-2645
View on ClinicalTrials.gov